Seven transmembrane receptors as nature's prototype allosteric protein: De-emphasizing the geography of binding

Molecular Pharmacology

Volumn 74, Issue 3, 2008, Pages 541-543

  Kenakin, Terry P ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND; MEMBRANE RECEPTOR; SEVEN TRANSMEMBRANE RECEPTOR; UNCLASSIFIED DRUG;

ALLOSTERISM; BINDING SITE; DIMERIZATION; DRUG RECEPTOR BINDING; KINETICS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; RECEPTOR BINDING; SHORT SURVEY;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; LIGANDS; PROTEIN BINDING; RECEPTORS, CELL SURFACE;

EID: 50449103386     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.050062     Document Type: Short Survey

References (23)

1. Baker JG and Hill SJ (2007) Multiple GPCR conformations and signaling pathways: Implications for antagonist affinity estimates. Trends Pharmacol Sci 28:374-381.
2. Burgen AS (1981) Conformational changes and drug action. Fed Proc 40:2723-2728.
3. Christopoulos A (2002) Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat Rev Drug Discov 1:198-210.
4. Christopoulos A and Kenakin T (2002) G-protein coupled receptor allosterism and complexing. Pharmacol Rev 54:323-374.
5. Costa T and Herz A (1989) Antagonists with negative intrinsic activity at δ-opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci U S A 86:7321-7325.
6. Frauenfelder H, Parak F, and Young RD (1988) Conformational substrates in proteins. Annu Rev Biophys Biophys Chem 17:451-479.
7. Frauenfelder H, Sligar SG, and Wolynes PG (1991) The energy landscapes and motions of proteins. Science 254:1598-1603.
8. Gonzalez E, Kulkarni H, Bolivar H, Mangano A, Sanchez R, Catano G, Nibbs RJ, Freedman BI, Quinones MP, Bamshad MJ, et al. (2005) The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 307:1434-1440.
9. Jakubík J, Bacáková L, El-Fakahany EE, and Tucek S (1997) Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol 52:172-179.
10. Jakubík J, Tucek S, and El-Fakahany EE (2002) Allosteric modulation by persistent binding of xanomeline of the interaction of competitive ligands with the M1 muscarinic acetylcholine receptor. J Pharmacol Exp Ther 301:1033-1041.
11. Kenakin TP (2004a) Allosteric modulators: the new generation of receptor antagonist. Mol Interv 4:222-229.
12. Kenakin T (2004b) Efficacy as a vector: the prevalence and paucity of inverse agonism. Mol Pharmacol 65:2-11.
13. Kenakin TP (2005) New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat Rev Drug Discov 4:919-927.
14. Kenakin T and Onaran O (2002) (2002) The ligand paradox between affinity and efficacy: Can you be there and not make a difference? Trends Pharmacol Sci 23:275-280.
15. Kew JN, Trube G, and Kemp JA (1996) A novel mechanism of activity-dependent NMDA receptor antagonism describes the effects of ifenprodil in rat cultured cortical neurons. J Physiol 497:761-772.
16. 4 muscarinic receptors in rat brain. J Pharmacol Exp Ther 322:316-323.
17. May LT, Leach K, Sexton PM, and Christopoulos A (2007) Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 47:1-51.
18. Onaran HO and Costa T (1997) Agonist efficacy and allosteric models of receptor action. Ann N Y Acad Sci 812:98-115.
19. Onaran HO, Scheer A, Cotecchia S, and Costa T (2000) A look at receptor efficacy. From the signaling network of the cell to the intramolecular motion of the receptor, in The Pharmacology of Functional, Biochemical, and Recombinant Systems (Kenakin TP, Angus JA), pp 217-260 Handbook of Experimental Pharmacology, vol. 148. Springer, Heidelberg, Germany.
20. Pargellis C, Tong L, Churchill L, Cirillo PF, Gilmore T, Graham AG, Grob PM, Hickey ER, Moss N, Pav S, et al. (2002) Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol 9:268-272.
21. Redka DS, Pisterzi LF, and Wells JW (2008) Binding of orthosteric ligands to the allosteric site of the M2 muscarinic cholinergic receptor. Mol Pharmacol 74:834-843.
22. Rees S, Morrow D, and Kenakin T (2002) PCR drug discovery through the exploitation of allosteric drug binding sites. Recept Channels 8:261-268.
23. Watson C, Jenkinson S, Kazmierski W, and Kenakin TP (2005) The CCR5 Receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry-inhibitor. Mol Pharmacol 67:1268-1282.